| Literature DB >> 22567155 |
Brandt D Pence1, Thomas W Lowder, K Todd Keylock, Victoria J Vieira Potter, Marc D Cook, Edward McAuley, Jeffrey A Woods.
Abstract
Research has shown that aging is associated with increased systemic inflammation as well as a reduction in the strength of immune responses. However, little evidence exists linking the decrease in cell-mediated immunity in older adults with other health parameters. We sought to examine the relationship between cell-mediated immunity as measured in vivo by the delayed-type hypersensitivity (DTH) response to candida antigen and demographic and physiological variables in older (65-80 y.o.) adults. Candida antigen response was not related to gender or obesity, or to a number of other physiological variables including fitness and body composition. However, positive responders had significantly lower serum C-reactive protein levels (CRP, p<0.05) vs. non-responders. Furthermore, subjects with CRP<4.75 mg•L(-1) had greater odds of developing a positive response compared to those with CRP>4.75 mg•L(-1). Therefore, positive responses to candida antigen in older adults appears to be related to lower levels of systemic inflammation.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22567155 PMCID: PMC3342252 DOI: 10.1371/journal.pone.0036403
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Percentage of subjects responding to DTH induced by candida antigen.
Bar insets represent number of positive responders (numerator) over total number of subjects (denominator) in each group.
Figure 2Magnitude of DTH response among positive responders to candida antigen.
Values are mean ± SEM.
Baseline characteristics.
| Responders | Non-Responders |
| |
| (N = 28) | (N = 82) | ||
|
| 69.7±1.1 | 69.9±0.6 |
|
| (68.0, 62.0–83.0) | (70.0, 60–83.0) | ||
|
| 19.7±0.8 | 20.0±0.4 |
|
| (19.1, 12.7–31.5) | (20.2, 19.3–30.4) | ||
|
| 26.8±0.8 | 28.0±0.5 |
|
| (27.0, 19.0–36.0) | (27.0, 20.0–41.0) | ||
|
| 76.5±2.9 | 78.0±1.7 |
|
| (75.3, 46.4–112.1) | (74.8, 50.5–113.5) | ||
|
| 33.0±1.2 | 34.0±0.9 |
|
| (33.4, 21.4–45.0) | (33.7, 16.4–52.9) | ||
|
| 72.4±2.2 | 75.4±1.5 |
|
| (75.0, 51.0–102.0) | (73.0, 54.0–120.0) | ||
|
| 0.6±0.1 | 0.8±0.1 |
|
| (1.0, 0.0–2.0) | (1.0, 0.0–2.0) |
Values shown are mean ± SEM. Parenthetical values shown are (median, range). yr: years of age. bpm: beats per minute. #: total number of medications.
Figure 3CRP values among responders and non-responders to DTH induced by candida antigen.
*Significantly different compared to non-responders (p<0.05). Values are mean ± SEM.
Odds ratios for positive DTH response by CRP level.
| CRP Quartile | OR (95% CI) |
| Responders (%) |
|
| 4.38 (0.82–23.42) |
| 8 (28.6%) |
|
| 6.94 (1.35–35.61) |
| 10 (35.7%) |
|
| 5.00 (0.95–26.23) |
| 8 (28.6%) |
|
| 1.00 | — | 2 (7.1%) |
Significantly increased odds of developing a positive DTH response (p<0.05). CI, confidence interval. % Responders represents percentage of total responders (N = 28) per group.
Correlation between DTH response to candida antigen and predictor variables in positive responders.
| Age | VO2 Peak | Weight | BMI | Body Fat | RHR | CRP | Meds | DTH | |
| (yr) | (ml·kg−1·min−1) | (kg) | (kg·m−2) | (%) | (bpm) | (mg·L−1) | (#) | (mm) | |
|
| 1.000 | 0.133 | −0.345 | −0.436 | −0.599 | −0.150 | −0.156 | −0.051 | −0.198 |
|
| — |
|
|
|
|
|
|
|
|
|
| 1.000 | 0.142 | 0.002 | 0.032 | −0.277 | −0.214 | −0.078 | 0.217 | |
|
| — |
|
|
|
|
|
|
| |
|
| 1.000 | 0.912 | 0.190 | −0.027 | 0.136 | −0.118 | 0.046 | ||
|
| — |
|
|
|
|
|
| ||
|
| 1.000 | 0.431 | 0.051 | 0.216 | −0.166 | 0.152 | |||
|
| — |
|
|
|
|
| |||
|
| 1.000 | 0.149 | 0.196 | −0.013 | 0.231 | ||||
|
| — |
|
|
|
| ||||
|
| 1.000 | −0.084 | −0.027 | −0.005 | |||||
|
| — |
|
|
| |||||
|
| 1.000 | −0.183 | −0.028 | ||||||
|
| — |
|
| ||||||
|
| 1.000 | −0.213 | |||||||
|
| — |
|
Significant correlation between variables (p<0.05). VO2, volume of oxygen consumption; BMI, body mass index; RHR, resting heart rate; CRP, C-reactive protein; Meds, anti-inflammatory medications; DTH, delayed-type hypersensitivity; bpm, beats per minute.
Figure 4Immune Function Intervention Trial CONSORT diagram.